There are currently 433 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Recruiting
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) * Hormonal (endocrine) Treatment
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/15/2025
Locations: Stamford Hospital, Stamford, Connecticut +29 locations
Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2025
Locations: Providence Medical Foundation, Fullerton, California +187 locations
Conditions: Breast Cancer
Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning
Recruiting
This study investigates the impact of four standard of care, monitored group exercise regimens (resistance training) on conditioning and hypertrophy in women previously treated for breast cancer. The study will compare two conditioning regimens (6-12-25 and 8x8) and two hypertrophy regimens (5/5/5 cluster sets and double training) to assess changes in VO2 max, muscle mass, and fat mass.
Gender:
FEMALE
Ages:
Between 20 years and 89 years
Trial Updated:
06/14/2025
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Cancer, Breast Cancer
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
Recruiting
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Research Site, Duarte, California +65 locations
Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, Biliary Tract Carcinoma, Squamous Non-Small Cell Lung Cancer
Preoperative Nicotine Cessation for Women With Breast Cancer Recommended for Reconstruction
Recruiting
Close to 20% of cancer patients currently use nicotine products. Nicotine use in breast cancer patients is associated with poorer overall outcomes, including worsened survival and increased surgical complications. Nicotine cessation is rarely addressed in breast cancer patients at the time of diagnosis and may be a missed opportunity to optimize patient outcomes. Patients that use nicotine products are not offered reconstruction at time of mastectomy or oncoplastics at the time of lumpectomy, wh... Read More
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
06/12/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Breast Cancer
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery
Recruiting
This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Memorial Health, Savannah, Georgia +7 locations
Conditions: Breast Cancer
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Recruiting
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Katmai Oncology Group - Anchorage, Anchorage, Alaska +43 locations
Conditions: Breast Cancer
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
06/10/2025
Locations: Fairbanks Memorial Hospital, Fairbanks, Alaska +461 locations
Conditions: Breast Cancer
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Recruiting
The purpose of this study is to test different doses of abemaciclib to find the best dose in participants while receiving hormone therapy and radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Memorial Sloan Kettering at Basking Ridge (All protocol activities), Basking Ridge, New Jersey +6 locations
Conditions: Metastatic Breast Cancer, Stage IV Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Breast Cancer Metastatic, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Hormone-receptor-positive Breast Cancer
Quantitative MRI Assessment of Breast Cancer Therapy Response
Recruiting
The goal of this observational study is to investigate and validate multi-parametric magnetic resonance imaging (MRI) modalities for assessment of breast cancer response to neoadjuvant chemotherapy in a multi-site and multi-MRI scanner platform setting. This study is conducted at Oregon Health \& Science University (OHSU), University of Washington (UW), and University of Iowa (UI) using Siemens, Philips, and General Electric MRI scanners, respectively. MRI is a type of scan that uses a very stro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Iowa, Iowa City, Iowa +3 locations
Conditions: Breast Cancer
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Recruiting
The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: BAPTIST ALLIANCE - MCI (Data Collection Only), Miami, Florida +9 locations
Conditions: Breast Cancer, Metastatic Triple-Negative Breast Cancer
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
Recruiting
To compare the outcomes of and responses to 2 different radiation therapy schedules (the standard radiation amount and number of doses versus less radiation and fewer doses) that are being given before having breast cancer surgery (cancer removal and reconstruction).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer